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Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤3. The primary 
endpoint was to evaluate the symptoms response rate 
produced by a radiotherapy regimen based on the delivery of 
4 radiotherapy fractions (5 Gy per fraction) with a twice daily 
fractionation in two consecutive days. 
 
Results: Twenty-nine patients were enrolled in this trial. 
Characteristics of the patients were: male/female: 16/13; 
median age: 66 years (range: 46-87). ECOG performance 
status was <3 in 25 patients (86.2%). With a median follow-up 
time of 5.0 months (range, 1 to 36 months), 9 G1-2 gastro-
intestinal (31%), 2 G1 haematological (6.8%) and 6 G1 skin 
(20.7%) toxicities were recorded. Only 1 patient (3.4%) 
experienced G3 acute gastro-intestinal toxicity. Of 29 
symptomatic patients, 27 showed an improvement or 
resolution of baseline symptoms (overall palliative response 
rate: 92.6%). Three-month overall survival was 92.2% (median 
survival time: not reached). In 25 patients with pain, a 
significant reduction of this symptom was recorded in terms 
of Drug Score (mean baseline Drug Score vs mean Drug Score 
at follow-up: 5.3 vs 4.0; p=0.04).  
 
Conclusion: Short-course accelerated radiotherapy on 
complicated bone metastases (20 Gy in twice daily fractions 
for 2 consecutive days) is tolerated and effective in terms of 
symptom relief. A phase III comparison against a standard 
palliative regimen (30 Gy in 10 fractions) has been planned in 
this patient population. 
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Purpose or Objective: More than 90% of patients with 
metastatic castration resistant prostate cancer (CRPC) have 
radiologic evidence of bone metastases. Radium-223 
dichloride therapy showed improved overall survival, quality 
of life and symptom control in patients with symptomatic 
bone metastases. Aim of the present study is to evaluate 
clinical course of patients treated in our centre including 
biochemical and imaging response.  
 
Material and Methods: Since November 2014 we started the 
treatment of symptomatic bone metastatic CRPC patients 
with Radium-223 dichloride (50kBq/kg, every 4 weeks). 
Before and after every administration the following 
parameter were recorded: PSA and alkaline phosphatase 
(ALP) values, pain numerical rating scale (NRS), performance 
status (ECOG scale), analgesic therapy and side effects 
(graded according to the CTCAE v. 4 classification). A whole 
body scintigraphy was performed before and one month after 
the treatment.  
 
Results: Twenty patients (total: 70 administrations) were 
treated. All patients showed increased PSA value and reduced 
ALP values. Performance status, evaluated with ECOG scale, 
was improved in all patients. Pain control was excellent, with 
reduction of NRS and analgesic therapies in all patients. Most 
patients showed only G1 toxicity: anaemia (15 pts), fatigue (3 
pts), diarrhea (1 pt), nausea (1 pt), and pain flare-up (6 pts). 
Eight patients completed the 6 planned cycles of therapy. Six 
patients discontinued treatment due to adverse events: 
anaemia (2 pts), pathological fracture of the femur (1 pt), 
severe bleeding (2 pts) and complications in uncontrolled 
diabetes (1 pt). The other patients are still under treatment. 
Whole body scintigraphy performed one month after the end 
of the treatment demonstrated in all patients a reduced 
intensity and number of uptake areas without correlation 
with PSA values. 
 
Conclusion: Treatment with Radium 223 in patients with 
CRPC and symptomatic bone metastases was tolerated in the 
majority of patients. High response rates in terms of 
symptom control and QoL improvement were recorded. 
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Purpose or Objective: To determine the results of 55 
patients with Superior Vena Cava Syndrome (SVCS) treated 
with radiotherapy. 
 
Material and Methods: Between September 2009 and 
September 2014, 55 patients with SVCS were treated at 
Operative Unity of Radiotherapy and Radiobiology, “Hospital 
Pugliese-Ciaccio”, Catanzaro. Of these 21 were women and 
34 men, with a median age at diagnosis of 61 years (range 33-
77 years).The most predominant symptoms were face or neck 
swelling (85%), upper swelling extremity (73%), dyspnea 
(70%), cough (62%), neck and vein distension (45%). 
Radiotherapy (RT) has been the only treatment in 6 of 11 
patients in which the rapidly progressive symptoms has not 
allowed to submit to a histologic diagnosis. For the patients 
which the histo-pathological diagnosis was known and for 
those in which to effect it, the treatment has included both 
the chemotherapy and the radiotherapy. The fractionation 
schedule usually has included initial fractions of 300-400 cGy 
(2-4 fractions) followed by conventional fractionation of 180-
200 cGy. The RT total dose delivered is varied by 2000 cGy to 
5000 cGy 
 
Results: With regard radiotherapy delivered, in 5 (9%) of the 
55 patient essays we have observed a complete regression of 
the SVCS, while in 27 (49%) the response has been partial, 
stability of illness has been underlined in 15 (27%) patients 
and disease progression in 8 (15%) patients. 
 
Conclusion: In summary, in the SVCS the clinical symptoms 
often requires an urgent intervention. Survival depend on the 
status of patient’s disease and on the histologic type of the 
tumor. Radiotherapy is effective in the treatment of the 
initial SVCS and in the patients that relapsed or with 
recurrent illness. The radiotherapy produces a good control 
of the symptoms. There is no necessity of ample fractions in 
the initial treatment. In the reirradiation, the radiotherapy 
on mediastinum is one of the most greater components of the 
palliation. Moreover, in presence laryngeal stridor the 
radiotherapy can be administered before the histological 
diagnosis is available. 
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